subscribeSubscribe
European Commission approves cystic fibrosis treatment for six to 11-year-olds

European Commission approves cystic fibrosis treatment for six to 11-year-olds
PHARMATIMES
11 Jan 2022
Share Share
Vertex Signs Reimbursement Agreement for KAFTRIO+Ivacaftor in Cystic Fibrosis

Vertex Signs Reimbursement Agreement for KAFTRIO+Ivacaftor in Cystic Fibrosis
BUSINESSWIRE
19 Nov 2021
Share Share
Vertex Announces FDA Approvals of TRIKAFTA® , SYMDEKO® and KALYDECO®

Vertex Announces FDA Approvals of TRIKAFTA® , SYMDEKO® and KALYDECO®
BIOSPACE
21 Dec 2020
Share Share
Symkevi/Kalydeco cleared for use in young CF patients

Symkevi/Kalydeco cleared for use in young CF patients
Selina McKee PHARMATIMES
01 Dec 2020
Share Share
Vertex to Present New Data at Virtual Cystic Fibrosis Conferences

Vertex to Present New Data at Virtual Cystic Fibrosis Conferences
BUSINESSWIRE
24 Sep 2020
Share Share
ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis

ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis
PRESS RELEASE
23 Sep 2020
Share Share
Vertex`s Kaftrio (ivacaftor/tezacaftor/elexacaftor) Receives Approval In Europe

Vertex`s Kaftrio (ivacaftor/tezacaftor/elexacaftor) Receives Approval In Europe
EMA
27 Aug 2020
Share Share
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
EUROPEANPHARMACEUTICALREVIEW
26 Aug 2020
Share Share
EU nod for Vertex CF therapy Kaftrio

EU nod for Vertex CF therapy Kaftrio
Selina McKee PHARMATIMES
24 Aug 2020
Share Share
Vertex and NHS Wales agree on Kaftrio reimbursement

Vertex and NHS Wales agree on Kaftrio reimbursement
Selina McKee PHARMA TIMES
24 Jul 2020
Share Share